Category:

24 July 2024

Significant Sales and Market Positioning Results in the Italian Nutraceutical Market

08 July 2024

Allegato 3F Giugno 2024

05 July 2024

Effectiveness of the merger by incorporation

22 June 2024

Internal dealing communication

18 June 2024

THE DISTRIBUTION OF IRON-BASED DIETARY SUPPLEMENTS KICKS OFF IN MEXICO

13 June 2024

A NEW STUDY HIGHLIGHTS THE EFFICACY, SUPERIORITY AND IMPROVED TOLERABILITY OF SIDERAL® COMPARED TO CONVENTIONAL IRON SUPPLEMENT TREATMENTS

12 June 2024

INITIATION OF SHARE BUY-BACK PROGRAM

29 May 2024

ASSUNZIONE QUALIFICA DI PMI

13 May 2024

PHARMANUTRA S.P.A. THE BOD APPROVES THE INTERIM MANAGEMENT REPORT AS AT 31 MARCH2024 AND THE 2023 SUSTAINABILITY REPORT

15 April 2024

THE MERGER BY INCORPORATION INTO PHARMANUTRA S.P.A. OF JUNIA PHARMA S.R.L. AND ALESCO S.R.L. HAS BEEN APPROVED

15 March 2024

PHARMANUTRA S.P.A.: THE BOD APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 DECEMBER 2023

26 February 2024

Approval of the merger plan

11 January 2024

EURO 100 MILLION IN REVENUE REACHED IN THE YEAR OF ITS 20TH ANNIVERSARY SINCE ESTABLISHMENT

08 January 2024

LOSS OF SME STATUS

21 December 2023

PUBLICATION OF THE 2024 CORPORATE EVENTS CALENDAR

08 November 2023

MODEL DISCLOSURE FOR TRANSACTIONS IN THE ISSUER’S SECURITIES

06 November 2023

BOD APPROVES INTERIM MANAGEMENT REPORT AS AT 30/09/2023

10 October 2023

PHARMANUTRA S.P.A.: INITIATION OF SHARE BUY-BACK PROGRAM

03 October 2023

PHARMANUTRA S.P.A.: FIRST SALES ON THE US MARKET

19 September 2023

PHARMANUTRA S.P.A.: HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2023

12 September 2023

POLICY FOR THE MANAGEMENT OF THE DIALOGUE WITH ALL SHAREHOLDERS OF PHARMANUTRA S.P.A.

1 2 … 11 >